26-07-2005: Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has granted MWG Biotech AG a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"This agreement with MWG, an international genomic solution provider, continues to highlight the value of the Alnylam-owned Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals. "By leveraging our portfolio of leading IP, we are creating value today and for the future by amassing an increasing number of license agreements with leading reagent and service providers. To date, fourteen companies have taken licenses for therapeutic or research product applications, including eight research product suppliers."
"This license strengthens our siRNA offering and is part of our commitment to build a high quality presence in siRNA design and production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG.
This is where you can add this news to your personal favourites
As part of their on-going investment in the Oligonucleotides and Sequencing market in the UK and Ireland, MWG Biotech announced the expansion of their sales team. Avril Hamilton joins as UK and Ireland Sales Manager and her appointment is seen as key to strengthening the sales and marketing ... more
Through the purchase of the GS 20 system, Eurofins | Medigenomix / MWG Biotech becomes the first international service provider in Germany to offer their customers access to the next generation of DNA sequencing technology via their production facility in Martinsried. According to the the c ... more
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has granted MWG Biotech AG a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family co ... more
Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financ ... more
Alnylam Pharmaceuticals, Inc. announced that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercia ... more
Alnylam Pharmaceuticals, Inc. and Cenix BioScience GmbH announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work resulted from an ongoing malaria research ... more
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the cur ... more